Introducing Akrotome’s patented FIRE

(Fluorescent Image Resection Enhancement)

Revolutionizing cancer resection surgery through
high resolution molecular imaging probes

FIRE: Read More

Fire’s growing reputation in the healthcare marketplace

Research

Blazing a New Trail in Guided Surgery and Diagnostics

Cancer-targeted molecular probes have the potential to revolutionize surgery and diagnostics. Offering unparalleled flexibility and outstanding performance, FIRE epitomizes the cutting edge of this technology. FIRE’s quenched, activity-based probe (qABP) technology guides surgeons by ensuring probe signal is only seen when cancer is detected, clearly delineating tumor tissue from healthy tissue and virtually eliminating spurious background fluorescence common in other probes. <more>

Patient outcomes

“Getting It All” – Better Cancer Resections with FIRE™– Guided Surgery

The Promise

With modern diagnostic and imaging technologies, cancer can be detected earlier than ever before. And with earlier detection comes the promise of a surgical cure—that is, the complete removal (or resection) of all tumor tissue from a patient. Research has shown that patients with surgical cures have fewer complications in recovery and a greatly enhanced survival rate when compared to patients who do not achieve surgical cures.  <more>

Investors

Outstanding Performance

Background

Advances in diagnostic methods have enabled the detection of cancer at the earliest stages when the chances for successful intervention are highest. For many solid tumors, the best chance for a cure is surgery. A surgical cure depends upon the complete removal of all cancer tissue from a patient (a “complete resection”). The main challenge of this approach is that it is very difficult for a surgeon to determine where diseased tissue ends and healthy tissue begins. <more>

Clinicians

FIRE™– A Flexible and Precise Molecular Probe Platform Expressly Designed for Cancer Surgeons

A critical factor in ensuring complete resection of a solid cancer tumor is the ability to determine where diseased tissue ends and healthy tissue begins. Our research, as well as our clinical collaborators, confirm that there is a pressing unmet clinical need: the ability to rapidly and globally assess the status of marginal tissue adjacent to a tumor while the patient is in the OR.  <more>

FIRE probes are currently in the clinical translation process for the intraoperative assessment of tumor margins for breast cancer and non-melanoma skin cancer. Future applications include brain, lung, and prostate cancers, as well as colon cancer diagnostics.